Vertex Pharmaceuticals Publishes Positive Phase 3 Data for IgA Nephropathy Treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-26
Category: health
Source: BioSpace (Vertex Pharmaceuticals)
Original source

Vertex Pharmaceuticals announced the publication of positive Phase 3 RAINIER trial results for povetacicept in the New England Journal of Medicine. The data showed a 52.0% reduction in proteinuria at Week 36, meeting both secondary endpoints. This highlights povetacicept's potential as a new therapeutic option for IgA Nephropathy, a chronic kidney disease.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai